PDCD1 and cancer: Immunotherapies, particularly immune checkpoint inhibitors (ICIs) targeting the programmed cell-death protein 1 (PD-1) and programmed cell-death 1 ligand 1 (PD-L1), have achieved remarkable progress in the treatment of numerous cancers (11–13).